PERJETA 420 mg Concentrate for solution for infusion 420 mg Concentrate for solution for infusion 14ml Vial
Product Overview
Perjeta (pertuzumab) 420 mg concentrate for solution for infusion 14ml vial is a highly specialized prescription medication. It is primarily used in the treatment of HER2-positive breast cancer. Developed by F. Hoffmann-La Roche Ltd., Perjeta is a monoclonal antibody. It specifically targets the HER2 receptor, preventing its dimerization. This action effectively inhibits cancer cell growth and survival. Perjeta is typically administered intravenously in combination with trastuzumab and chemotherapy. This forms a potent regimen against aggressive forms of breast cancer. This medication plays a crucial role in both early-stage and metastatic HER2-positive breast cancer. It significantly improves patient outcomes. You can often find this specialized medication listed on leading pharmaceutical e-commerce platforms like Nahdi Online, , and , offering access to essential treatments.
Benefits of Use
- Targeted therapy specifically designed for HER2-positive breast cancer.
- Significantly improves progression-free survival and overall survival rates when used in combination with trastuzumab and chemotherapy.
- Works by inhibiting HER2 receptor dimerization, thereby blocking key signaling pathways that drive cancer cell growth.
- An essential component of comprehensive treatment regimens for both neoadjuvant/adjuvant and metastatic settings.
- Manufactured by F. Hoffmann-La Roche Ltd., ensuring high quality and rigorous standards.
How to Use
- Perjeta must be administered by a qualified healthcare professional in a clinical setting.
- The concentrate for solution for infusion must be diluted before intravenous administration.
- The typical dosing regimen involves a loading dose followed by maintenance doses every three weeks.
- Treatment duration and specific dosage will be determined by your oncology specialist based on your medical condition and treatment plan.
- Regular monitoring for potential side effects and cardiac function (LVEF) is essential throughout the treatment course.
Caution & Warnings
- Perjeta can cause cardiac dysfunction, including a decrease in left ventricular ejection fraction (LVEF); regular cardiac monitoring is required.
- Infusion-related reactions may occur, ranging from mild to severe; appropriate medical management should be available.
- Severe hypersensitivity reactions and anaphylaxis have been reported; monitor patients during and after infusion.
- Embryo-fetal toxicity: Perjeta can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.
- Use effective contraception during treatment and for 7 months following the last dose of Perjeta.
- This medication should only be used under the supervision of an experienced oncologist.
Ingredients
Active Ingredient:
- Pertuzumab 420 mg
Excipients:
- Histidine
- Sucrose
- Polysorbate 20
- Water for Injection
Product Details
- Brand: Perjeta
- Scientific Name: Pertuzumab
- Strength: 420 mg
- Form: Concentrate for solution for infusion
- Volume: 14 ml vial
- Manufacturer: F. Hoffmann-La Roche Ltd.
- Drug Type: Prescription Only Medicine (POM)
- Storage: Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light.
| Gtin | 0107613326043342 |
|---|---|
| Recommended Sale Price | 10178.05 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | PERTUZUMAB |
| SFDA Reg. No | 277-24-14 |
| IBC | 0107613326043342 |
| Drug Type | Prescription Only Medicine |
| Scientific Name | Pertuzumab |
| Strength | 420 |
| Strength Unit | mg |
| Form | Concentrate for solution for infusion |
| Admin Route | Intravenous |
| Size | 14 |
| Size Unit | ml |
| Package Types | Vial |
| Package Size | 14ml |
| shelfLife | 24 months |
| Storage conditions | Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light. |
| Refrigerator Storage | Yes |
